Literature DB >> 29295866

Connexin 43 gap junctions contribute to brain endothelial barrier hyperpermeability in familial cerebral cavernous malformations type III by modulating tight junction structure.

Allison M Johnson1, James P Roach2, Anna Hu1, Svetlana M Stamatovic1, Michal R Zochowski3, Richard F Keep4,5, Anuska V Andjelkovic1,4.   

Abstract

Familial cerebral cavernous malformations type III (fCCM3) is a disease of the cerebrovascular system caused by loss-of-function mutations in ccm3 that result in dilated capillary beds that are susceptible to hemorrhage. Before hemorrhage, fCCM3 lesions are characterized by a hyperpermeable blood-brain barrier (BBB), the key pathologic feature of fCCM3. We demonstrate that connexin 43 (Cx43), a gap junction (GJ) protein that is incorporated into the BBB junction complex, is up-regulated in lesions of a murine model of fCCM3. Small interfering RNA-mediated ccm3 knockdown (CCM3KD) in brain endothelial cells in vitro increased Cx43 protein expression, GJ plaque size, GJ intracellular communication (GJIC), and barrier permeability. CCM3KD hyperpermeability was rescued by GAP27, a peptide gap junction and hemichannel inhibitor of Cx43 GJIC. Tight junction (TJ) protein, zonula occludens 1 (ZO-1), accumulated at Cx43 GJs in CCM3KD cells and displayed fragmented staining at TJs. The GAP27-mediated inhibition of Cx43 GJs in CCM3KD cells restored ZO-1 to TJ structures and reduced plaque accumulation at Cx43 GJs. The TJ protein, Claudin-5, was also fragmented at TJs in CCM3KD cells, and GAP27 treatment lengthened TJ-associated fragments and increased Claudin 5-Claudin 5 transinteraction. Overall, we demonstrate that Cx43 GJs are aberrantly increased in fCCM3 and regulate barrier permeability by a TJ-dependent mechanism.-Johnson, A. M., Roach, J. P., Hu, A., Stamatovic, S. M., Zochowski, M. R., Keep, R. F., Andjelkovic, A. V. Connexin 43 gap junctions contribute to brain endothelial barrier hyperpermeability in familial cerebral cavernous malformations type III by modulating tight junction structure.

Entities:  

Keywords:  PDCD10; cell-cell interaction; permeability; zonula occludens-1

Mesh:

Substances:

Year:  2018        PMID: 29295866      PMCID: PMC5901390          DOI: 10.1096/fj.201700699R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  44 in total

1.  An in vitro model for endothelial permeability: assessment of monolayer integrity.

Authors:  P W Kazakoff; T R McGuire; E B Hoie; M Cano; P L Iversen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-12       Impact factor: 2.416

Review 2.  STRIPAK complexes: structure, biological function, and involvement in human diseases.

Authors:  Juyeon Hwang; David C Pallas
Journal:  Int J Biochem Cell Biol       Date:  2013-12-11       Impact factor: 5.085

Review 3.  The connexin 43 C-terminus: A tail of many tales.

Authors:  Edward Leithe; Marc Mesnil; Trond Aasen
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-05-16       Impact factor: 3.747

4.  Vascular permeability in cerebral cavernous malformations.

Authors:  Abdul G Mikati; Omaditya Khanna; Lingjiao Zhang; Romuald Girard; Robert Shenkar; Xiaodong Guo; Akash Shah; Henrik B W Larsson; Huan Tan; Luying Li; Matthew S Wishnoff; Changbin Shi; Gregory A Christoforidis; Issam A Awad
Journal:  J Cereb Blood Flow Metab       Date:  2015-05-13       Impact factor: 6.200

5.  A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.

Authors:  David A McDonald; Robert Shenkar; Changbin Shi; Rebecca A Stockton; Amy L Akers; Melanie H Kucherlapati; Raju Kucherlapati; James Brainer; Mark H Ginsberg; Issam A Awad; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2010-10-11       Impact factor: 6.150

6.  PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk.

Authors:  Svetlana M Stamatovic; Nikola Sladojevic; Richard F Keep; Anuska V Andjelkovic
Journal:  Acta Neuropathol       Date:  2015-09-18       Impact factor: 17.088

7.  The gap junction protein connexin43 interacts with the second PDZ domain of the zona occludens-1 protein.

Authors:  B N Giepmans; W H Moolenaar
Journal:  Curr Biol       Date:  1998 Jul 30-Aug 13       Impact factor: 10.834

8.  A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein.

Authors:  Marilyn Goudreault; Lisa M D'Ambrosio; Michelle J Kean; Michael J Mullin; Brett G Larsen; Amy Sanchez; Sidharth Chaudhry; Ginny I Chen; Frank Sicheri; Alexey I Nesvizhskii; Ruedi Aebersold; Brian Raught; Anne-Claude Gingras
Journal:  Mol Cell Proteomics       Date:  2008-09-08       Impact factor: 5.911

9.  Connexin43 is highly localized to sites of disturbed flow in rat aortic endothelium but connexin37 and connexin40 are more uniformly distributed.

Authors:  J E Gabriels; D L Paul
Journal:  Circ Res       Date:  1998-09-21       Impact factor: 17.367

10.  Identification of the calmodulin binding domain of connexin 43.

Authors:  Yubin Zhou; Wei Yang; Monica M Lurtz; Yiming Ye; Yun Huang; Hsiau-Wei Lee; Yanyi Chen; Charles F Louis; Jenny J Yang
Journal:  J Biol Chem       Date:  2007-09-27       Impact factor: 5.157

View more
  22 in total

Review 1.  Brain endothelial cell junctions after cerebral hemorrhage: Changes, mechanisms and therapeutic targets.

Authors:  Richard F Keep; Anuska V Andjelkovic; Jianming Xiang; Svetlana M Stamatovic; David A Antonetti; Ya Hua; Guohua Xi
Journal:  J Cereb Blood Flow Metab       Date:  2018-05-08       Impact factor: 6.200

Review 2.  Brain Disorders and Chemical Pollutants: A Gap Junction Link?

Authors:  Marc Mesnil; Norah Defamie; Christian Naus; Denis Sarrouilhe
Journal:  Biomolecules       Date:  2020-12-31

3.  An In Vivo Mouse Model to Study Blood-Brain Barrier Destabilization in the Chronic Phase of Stroke.

Authors:  Svetlana M Stamatovic; Chelsea M Phillips; Richard F Keep; Anuska V Andjelkovic
Journal:  Methods Mol Biol       Date:  2022

4.  Acute Methylglyoxal-Induced Damage in Blood-Brain Barrier and Hippocampal Tissue.

Authors:  Lílian Juliana Lissner; Krista Minéia Wartchow; Leticia Rodrigues; Larissa Daniele Bobermin; Ederson Borba; Vitor Gayger Dias; Fernanda Hansen; André Quincozes-Santos; Carlos-Alberto Gonçalves
Journal:  Neurotox Res       Date:  2022-09-03       Impact factor: 3.978

Review 5.  Connexin and Pannexin Large-Pore Channels in Microcirculation and Neurovascular Coupling Function.

Authors:  Pía C Burboa; Mariela Puebla; Pablo S Gaete; Walter N Durán; Mauricio A Lillo
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

6.  Development of the Neuro-Immune-Vascular Plexus in the Ventricular Zone of the Prenatal Rat Neocortex.

Authors:  Elisa Penna; Jon M Mangum; Hunter Shepherd; Veronica Martínez-Cerdeño; Stephen C Noctor
Journal:  Cereb Cortex       Date:  2021-03-05       Impact factor: 5.357

Review 7.  Function of Connexins in the Interaction between Glial and Vascular Cells in the Central Nervous System and Related Neurological Diseases.

Authors:  Yinan Zhao; Yanguo Xin; Zhiyi He; Wenyu Hu
Journal:  Neural Plast       Date:  2018-06-10       Impact factor: 3.599

8.  The year in review: progress in brain barriers and brain fluid research in 2018.

Authors:  Richard F Keep; Hazel C Jones; Lester R Drewes
Journal:  Fluids Barriers CNS       Date:  2019-02-05

Review 9.  Modeling blood-brain barrier pathology in cerebrovascular disease in vitro: current and future paradigms.

Authors:  Anuska V Andjelkovic; Svetlana M Stamatovic; Chelsea M Phillips; Gabriela Martinez-Revollar; Richard F Keep
Journal:  Fluids Barriers CNS       Date:  2020-07-16

Review 10.  Role of Connexins 30, 36, and 43 in Brain Tumors, Neurodegenerative Diseases, and Neuroprotection.

Authors:  Oscar F Sánchez; Andrea V Rodríguez; José M Velasco-España; Laura C Murillo; Jhon-Jairo Sutachan; Sonia-Luz Albarracin
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.